Clinical Trial

CINC424A2X01B Rollover Protocol

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.
Protocol Amendment History 5 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-03
notable Trial sites reduced: 101 -> 97 locations 2026-07-03
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-06-23
notable Trial sites expanded: 97 -> 101 locations 2026-06-23
minor Completion pushed: 2027-09-16 -> 2032-04-05 2026-06-23
Trial Details
NCT Number NCT02386800
Lead Sponsor Novartis Pharmaceuticals
Conditions Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
Enrollment 279 participants
Start Date 2015-03-05
Primary Completion 2027-09-16 (estimated)
Study Completion 2032-04-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-02